{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SMC",
    "query": {
      "intervention": "SMC"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 69,
    "total_pages": 7,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=SMC&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-09-03T02:50:36.936Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00333515",
      "title": "Pharmacokinetic (PK) and Safety Study of Plasma-derived Human Butyrylcholinesterase Administered Intravenously",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers",
        "Chemical Terrorism",
        "Chemical Warfare"
      ],
      "interventions": [
        {
          "name": "Human Butyrylcholinesterase (HuBChE) derived from human plasma",
          "type": "DRUG"
        },
        {
          "name": "Placebo: Normal saline",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Baxalta now part of Shire",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 28,
      "start_date": "2007-01-01",
      "completion_date": "2008-08-01",
      "has_results": false,
      "last_update_posted_date": "2021-05-05",
      "last_synced_at": "2026-09-03T02:50:36.936Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333515"
    },
    {
      "nct_id": "NCT04265456",
      "title": "A Phase 1 Study to Evaluate Pregabalin and Acetaminophen in Healthy Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Postoperative Pain"
      ],
      "interventions": [
        {
          "name": "Pregabalin 100mg",
          "type": "DRUG"
        },
        {
          "name": "Acetaminophen 1300mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Nevakar, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 63,
      "start_date": "2020-01-14",
      "completion_date": "2020-07-22",
      "has_results": false,
      "last_update_posted_date": "2020-08-05",
      "last_synced_at": "2026-09-03T02:50:36.936Z",
      "location_count": 1,
      "location_summary": "Pasadena, California",
      "locations": [
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04265456"
    },
    {
      "nct_id": "NCT06585488",
      "title": "A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in Participants With Advanced or Metastatic Solid Tumors With KRAS Mutations or Amplification",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Solid Tumors",
        "Advanced Non-squamous Non-small-cell Lung Cancer",
        "Advanced Colorectal Cancer",
        "Advanced Pancreatic Ductal Adenocarcinoma",
        "Advanced Gastric Cancer",
        "Advanced Gastroesophageal Junction Cancer",
        "Advanced Esophageal Adenocarcinoma"
      ],
      "interventions": [
        {
          "name": "BGB-53038",
          "type": "DRUG"
        },
        {
          "name": "Tislelizumab",
          "type": "DRUG"
        },
        {
          "name": "Cetuximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BeOne Medicines",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 47,
      "start_date": "2024-12-13",
      "completion_date": "2026-04-23",
      "has_results": false,
      "last_update_posted_date": "2026-07-08",
      "last_synced_at": "2026-09-03T02:50:36.936Z",
      "location_count": 4,
      "location_summary": "Los Angeles, California • Kansas City, Kansas • Baltimore, Maryland + 1 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06585488"
    },
    {
      "nct_id": "NCT03954106",
      "title": "A Safety and Efficacy Study of Defibrotide in the Prevention of Chimeric Antigen Receptor-T-cell-associated Neurotoxicity",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "DLBCL",
        "Neurotoxicity Syndromes"
      ],
      "interventions": [
        {
          "name": "Defibrotide",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Jazz Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2019-10-04",
      "completion_date": "2020-09-30",
      "has_results": true,
      "last_update_posted_date": "2021-12-09",
      "last_synced_at": "2026-09-03T02:50:36.936Z",
      "location_count": 5,
      "location_summary": "Phoenix, Arizona • Baltimore, Maryland • Boston, Massachusetts + 1 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03954106"
    },
    {
      "nct_id": "NCT02174224",
      "title": "At-risk Intervention and Mentoring Evaluation",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Violence"
      ],
      "interventions": [
        {
          "name": "Brief Intervention",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Case Management",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard Medical Care",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Denver Health and Hospital Authority",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "24 Years",
        "sex": "ALL",
        "summary": "14 Years to 24 Years"
      },
      "enrollment_count": 133,
      "start_date": "2014-06",
      "completion_date": "2019-04",
      "has_results": false,
      "last_update_posted_date": "2021-02-11",
      "last_synced_at": "2026-09-03T02:50:36.936Z",
      "location_count": 1,
      "location_summary": "Denver, Colorado",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02174224"
    },
    {
      "nct_id": "NCT05141266",
      "title": "Healthy Opioid Prescription Engagement",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Opioid Misuse",
        "Opioid-Related Disorders",
        "Pharmacist-Patient Relations"
      ],
      "interventions": [
        {
          "name": "Patient Navigation",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard Medication Counseling (SMC)",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL",
        "OTHER"
      ],
      "sponsor": "Jerry Cochran",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 350,
      "start_date": "2021-11-08",
      "completion_date": "2027-07-01",
      "has_results": false,
      "last_update_posted_date": "2026-07-17",
      "last_synced_at": "2026-09-03T02:50:36.936Z",
      "location_count": 1,
      "location_summary": "Salt Lake City, Utah",
      "locations": [
        {
          "city": "Salt Lake City",
          "state": "Utah"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05141266"
    },
    {
      "nct_id": "NCT02082522",
      "title": "Efficacy and Safety Study of PDT Using Photofrin in Unresectable Advanced Perihilar Cholangiocarcinoma (OPUS)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hilar Cholangiocarcinoma"
      ],
      "interventions": [
        {
          "name": "Photodynamic therapy-Photofrin",
          "type": "DRUG"
        },
        {
          "name": "Stenting procedure",
          "type": "PROCEDURE"
        },
        {
          "name": "Chemotherapy regimen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "PROCEDURE"
      ],
      "sponsor": "Concordia Laboratories Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 28,
      "start_date": "2014-11-12",
      "completion_date": "2017-01-12",
      "has_results": true,
      "last_update_posted_date": "2019-08-28",
      "last_synced_at": "2026-09-03T02:50:36.936Z",
      "location_count": 18,
      "location_summary": "Goodyear, Arizona • Scottsdale, Arizona • Los Angeles, California + 14 more",
      "locations": [
        {
          "city": "Goodyear",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02082522"
    },
    {
      "nct_id": "NCT07287397",
      "title": "Study is to Assess the Safety and Tolerability of VTx-002 in Participants With ALS",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Amyotrophic Lateral Sclerosis"
      ],
      "interventions": [
        {
          "name": "VTx-002",
          "type": "GENETIC"
        },
        {
          "name": "Preventative (Prophylactic) Medication - Corticosteroids: Methylprednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "GENETIC",
        "DRUG"
      ],
      "sponsor": "Vector Y Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2025-12-19",
      "completion_date": "2027-10-15",
      "has_results": false,
      "last_update_posted_date": "2026-08-26",
      "last_synced_at": "2026-09-03T02:50:36.936Z",
      "location_count": 7,
      "location_summary": "Phoenix, Arizona • San Diego, California • Jacksonville, Florida + 4 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07287397"
    },
    {
      "nct_id": "NCT00548691",
      "title": "Safety and Tolerability of FCM vs Standard of Care in Treating Iron Deficiency Anemia in Chronic Kidney Disease Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Anemia"
      ],
      "interventions": [
        {
          "name": "Ferric Carboxymaltose",
          "type": "DRUG"
        },
        {
          "name": "Standard Medical Care (SMC)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "American Regent, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 513,
      "start_date": "2007-10",
      "completion_date": "2009-07",
      "has_results": true,
      "last_update_posted_date": "2018-02-20",
      "last_synced_at": "2026-09-03T02:50:36.936Z",
      "location_count": 1,
      "location_summary": "Norristown, Pennsylvania",
      "locations": [
        {
          "city": "Norristown",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00548691"
    },
    {
      "nct_id": "NCT03972306",
      "title": "A Study To Investigate The Pharmacokinetics, Safety, And Tolerability Of Subcutaneous Ocrelizumab Administration In Participants With Multiple Sclerosis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Multiple Sclerosis (MS)"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        },
        {
          "name": "rHuPH20",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 134,
      "start_date": "2019-08-12",
      "completion_date": "2025-06-03",
      "has_results": false,
      "last_update_posted_date": "2025-07-08",
      "last_synced_at": "2026-09-03T02:50:36.936Z",
      "location_count": 18,
      "location_summary": "Aurora, Colorado • Washington D.C., District of Columbia • Alexandria, Louisiana + 15 more",
      "locations": [
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Alexandria",
          "state": "Louisiana"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03972306"
    }
  ]
}